Evidence map›Paper›PMID 29110154›Full record

ArticleInflammation2018

RX-207, a Small Molecule Inhibitor of Protein Interaction with Glycosaminoglycans (SMIGs), Reduces Experimentally Induced Inflammation and Increases Survival Rate in Cecal Ligation and Puncture (CLP)-Induced Sepsis.

Stefan Juhas, Nicholas Harris, Gabriela Il'kova, Pavol Rehák, Ferenc Zsila, Faina Yurgenzon Kogan, Orly Lahmy, Regina Zhuk, Paul Gregor, Juraj Koppel

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Stefan JuhasInstitute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia.
Nicholas HarrisRimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel. nharris@braude.ac.il.
Gabriela Il'kovaInstitute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia.
Pavol RehákInstitute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia.
Ferenc ZsilaBiomolecular Self-Assembly Group, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
Faina Yurgenzon KoganRimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel.
Orly LahmyRimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel.
Regina ZhukRimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel.
Paul GregorRimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel. paul@gismotherapeutics.com.
Juraj KoppelInstitute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia.
Institute of Animal Physiology of the Slovak Academy of Sciences · SKSlovak Academy of Sciences · SKGismo Therapeutics (United States) · USHungarian Academy of Sciences · HU

Funding

ERDF ITMS 26220120066
6 · The paper itself

Abstract

The fused quinazolinone derivative, RX-207, is chemically and functionally related to small molecule inhibitors of protein binding to glycosaminoglycans (SMIGs). Composed of a planar aromatic amine scaffold, it inhibits protein binding to glycosaminoglycans (GAGs). RX-207 reduced neutrophil migration in thioglycollate-induced peritonitis (37%), inhibited carrageenan-induced paw edema (32%) and cerulein-induced pancreatitis (28%), and increased animal survival in the mouse model of cecal ligation and puncture (CLP)-induced sepsis (60%). The mechanism of RX-207 action, analyzed by UV spectroscopy, confirmed that which was elucidated for chemically related anti-inflammatory SMIGs. RX-207 binding to cell surface GAGs can account for the inhibition of neutrophil recruitment via the micro-vasculature and as a consequence, the reduction of neutrophil mediated tissue damage in the animal models of inflammation and improved survival of mice in CLP-induced sepsis.

Indexed as

AnimalsAnti-Inflammatory AgentsCecumCell AdhesionDisease Models, AnimalEdemaGlycosaminoglycansLigationMice, Inbred BALB CNeutrophil InfiltrationNeutrophilsPancreatitisPeritonitisProtein BindingPuncturesQuinazolinonesAnti-Inflammatory AgentsGlycosaminoglycansQuinazolinonesglycosaminoglycanheparin binding proteininflammationneutrophilsepsis

Identifiers

PMID29110154
OpenAlexW2768005529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.